Stock Market Reviews

Read and share opinions on MNKD (MannKind Corporation) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• MannKind Shares FUROSCIX® Business Updates
  Dec 23, 2025
• Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset
  Dec 3, 2025
• MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
  Dec 1, 2025
• MannKind to Present at the Jefferies Global Healthcare Conference
  Nov 11, 2025
• MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
  Nov 10, 2025
• MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ...
  Nov 8, 2025
• MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion
  Nov 8, 2025
• MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
  Nov 6, 2025
• MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
  Nov 5, 2025
• MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
  Nov 5, 2025
• MannKind: Q3 Earnings Snapshot
  Nov 5, 2025
• MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
  Nov 5, 2025
• MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
  Oct 29, 2025

MNKD News

• Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
  This biotech innovator in inhaled therapeutics reported a notable insider sale amid ongoing product development and licensing activity.
  Dec 24, 2025
• MannKind Shares FUROSCIX® Business Updates
  FDA approves FUROSCIX® for use in pediatric patients weighing 43kg or aboveUSPTO issues five patents for FUROSCIX ReadyFlow™ Autoinjector WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced two business updates—approval of the FUROSCIX® (furosemide) On-body Infusor for pediatric patients and issuance of additional intellectual property protection for the investigational-stage FUROSCIX ReadyFlow™ Autoinjector, which
  Dec 23, 2025
• Is There Now an Opportunity in MannKind After This Year’s Share Price Pullback?
  If you have been wondering whether MannKind at around $5.43 is a bargain or a value trap, you are not alone. This stock tends to attract investors who like under followed stories with asymmetric upside. Despite being down 17.7% year to date and 19.1% over the last year, the stock is still up 18.8% over three years and 87.2% over five years. This suggests the long term narrative has been much more constructive than the recent pullback implies. Much of the recent share price action has been...
  Dec 3, 2025
• Reassessing MannKind (MNKD) Valuation After Recent Share Price Reset
  MannKind (MNKD) has been quietly grinding higher, with shares up about 4% over the past week and roughly 5% in the past 3 months, even as the year-to-date return remains negative. See our latest analysis for MannKind. That recent 1 day share price return of almost 3% looks more like part of a cautious reset than a full trend change. The 1 year total shareholder return is still firmly negative, but the 5 year total shareholder return shows meaningful gains. This suggests sentiment is...
  Dec 3, 2025
• MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
  If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and convenient option to address episodes of fluid buildup at home, benefiting patients, providers and payorsPDUFA target action date of July 26, 2026 WESTLAKE VILLAGE, Calif. and BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug
  Dec 1, 2025
• MannKind to Present at the Jefferies Global Healthcare Conference
  DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that Michael Castagna, Chief Executive Officer, and Chris Prentiss, Chief Financial Officer, are scheduled to present and share updates during the Jefferies London Healthcare Conference on Wednesday, November 19, at 6:30 am ET/11:30 am GMT. The link to the live audio webcast of the session is available on MannKind Corporation’s website at: https://investors.mannkindc
  Nov 11, 2025
• MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
  MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring dataThis outcome does not impact the development of MNKD-102, MannKind’s dry powder inhalation (DPI) formulation of clofazimine, which remains under consideration for future clinical advancementMannKind extends its sincere gratitude to the study par
  Nov 10, 2025
• MannKind Corp (MNKD) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic Expansions ...
  MannKind Corp (MNKD) reports a record $82 million in revenue, driven by Tyvaso DPI, while navigating integration challenges and competitive pressures.
  Nov 8, 2025
• MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion
  MannKind (MNKD) caught investor attention after its third-quarter earnings revealed revenue growth ahead of forecasts, fueled by continued momentum from Afrezza and Tyvaso DPI. Strong commercial execution also contributed to better-than-expected performance. See our latest analysis for MannKind. MannKind’s recent string of positive updates, including robust Q3 revenues, new pipeline assets from the scPharmaceuticals acquisition, and new FDA reviews underway, helped the company recapture...
  Nov 8, 2025
• Will Rising Costs and Revenue Growth Shift MannKind's (MNKD) Long-Term Investment Outlook?
  MannKind Corporation recently reported its third quarter 2025 financial results, disclosing revenue of US$82.13 million, up from US$70.08 million a year ago, while net income fell to US$7.99 million from US$11.55 million. This mix of higher revenue but lower profitability highlights continued sales momentum alongside rising costs or margin pressures within the business. We'll explore how MannKind's Q3 revenue growth, despite lower net income, influences the company's long-term investment...
  Nov 7, 2025
• MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
  $100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciencesAlfred E. Mann Charities and MannKind are partnering with The Diabetes Link to launch the effort in November for Diabetes Awareness Month DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred
  Nov 6, 2025
• MannKind: Q3 Earnings Snapshot
  DANBURY, Conn. AP) — MannKind Corp. MNKD) on Wednesday reported third-quarter profit of $8 million.
  Nov 5, 2025
• MannKind (MNKD) Tops Q3 Earnings and Revenue Estimates
  MannKind (MNKD) delivered earnings and revenue surprises of +200.00% and +1.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025
• MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
  Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
  Nov 5, 2025
• MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
  Conference call today at 9:00 am ETQ3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue growth with FUROSCIX®Program updates: sBLA for Afrezza® in pediatric population accepted for FDA review; PDUFA date of May 29, 2026FUROSCIX ReadyFlow™ Autoinjector sNDA submitted to the FDA MNKD-101 NTM global Phase 3 trial (ICoN-1) achieved interim enrollment target ahead of schedule M
  Nov 5, 2025
• Great week for MannKind Corporation (NASDAQ:MNKD) institutional investors after losing 22% over the previous year
  Key Insights Institutions' substantial holdings in MannKind implies that they have significant influence over the...
  Nov 1, 2025
• Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?
  Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 30, 2025
• MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
  DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025. MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A repl
  Oct 29, 2025
• United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt
  The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he
  Oct 21, 2025
• MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
  If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) seeking approval for Afrezza (ins
  Oct 13, 2025
• MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
  DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind’s double-digit revenue growth, driven by FUROSCIX® (furosemide injection), an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind’s commercial an
  Oct 7, 2025
• Does MannKind (NASDAQ:MNKD) Deserve A Spot On Your Watchlist?
  It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
  Oct 5, 2025
• MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
  MannKind CMO MannKind appoints Dr. Ajay Ahuja as EVP, Chief Medical Officer WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced the appointment of Ajay Ahuja, MD, MBA, as Chief Medical Officer, effective today. Dr. Ahuja will report directly to Michael Castagna, PharmD,
  Sep 29, 2025
• Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?
  Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
  Sep 10, 2025
• MannKind (MNKD): A Fresh Look at Valuation Following New United Therapeutics Deal Expansion
  It’s not every day that a partnership update gets investors talking, but that’s exactly what happened with MannKind (MNKD) this week. The company just announced an amendment to its license and collaboration agreement with United Therapeutics, which expands their deal to cover an additional development product. This isn’t just a technical detail. MannKind will see a $5 million upfront payment, has a shot at another $35 million if development milestones are hit, and stands to collect royalties...
  Sep 8, 2025

MNKD Reviews

• OptionSpectre

  Dec 30, 2025

  $MNKD Chasing a miracle while the clock keeps ticking.

  Sell

• PixelBroker

  Dec 29, 2025

  $MNKD Injecting some serious innovation into the diabetes game—this company is like a superhero for sugar levels, ready to save the day!

  Buy

• TickerPhantom

  Dec 29, 2025

  $MNKD This biotech company is pioneering advancements in diabetes management, exhibiting a strong commitment to improving patient outcomes. Its innovative approach and partnerships signal promise for future developments in healthcare.

  Buy

• LazyQuant

  Dec 29, 2025

  $MNKD They’re working on some sweet technology. If only my homework could be solved as easily as their science stuff!

  Buy

• BuyLowBoi

  Dec 29, 2025

  $MNKD Innovatin' in diabetes tech, could be a game changer!

  Buy

• BearishBoi

  Dec 29, 2025

  $MNKD This feels like the underdog who keeps showing up to the race with a banana peel in one hand. You gotta root for 'em!

  Buy

• VolatilityStrike

  Dec 29, 2025

  $MNKD This innovative firm is making strides in the biopharmaceutical sector, with promising developments that could significantly address unmet medical needs, suggesting a bright future ahead.

  Buy

• EquityAssault

  Dec 28, 2025

  $MNKD Still waiting for this one to actually go somewhere.

  Sell

• MarginMarauder

  Dec 28, 2025

  $MNKD This stock is like a magic trick – it pulls profits out of thin air! Just watch it closely.

  Buy

• CashMeOutside

  Dec 28, 2025

  $MNKD Got some intriguing moves; will it be a game changer or just noise?

  Buy

• BearHunter

  Dec 26, 2025

  $MNKD It's like they’ve got a secret recipe for success, but instead of food, it's all about inhalers. Talk about a breath of fresh air!

  Buy

• TickerTyrant

  Dec 26, 2025

  $MNKD This company is more like a man down than a kind hero.

  Sell

• BuyTheDipBro

  Dec 25, 2025

  $MNKD In the game to change lives, makin' health moves, ya dig?

  Buy

• MarketMatrix

  Dec 25, 2025

  $MNKD This stock is like your buddy who tries really hard to impress but sometimes trips over their own feet.

  Sell

• CashKiller

  Dec 25, 2025

  $MNKD Another biotech that promises the moon but delivers dust.

  Sell

• MarketMarauder

  Dec 25, 2025

  $MNKD Stumbling in a marathon, and it’s not even close.

  Sell

• TickerFlux

  Dec 25, 2025

  $MNKD In the fierce race of biotech, every breakthrough counts, but so does every setback. The pressure to deliver can feel suffocating, with lives and livelihoods at stake!

  Sell

• VolatilityNomad

  Dec 25, 2025

  $MNKD Chasing a dream that only seems to get hazier.

  Sell

• CapitalRush

  Dec 24, 2025

  $MNKD This biopharmaceutical firm is dedicated to developing innovative treatments for diabetes and other serious conditions. Their commitment to research and strong pipeline could position them favorably within the healthcare sector.

  Buy

• TradeNinja

  Dec 24, 2025

  $MNKD If all else fails, just remember: science can sometimes lead to magical moments. And this one’s got wand-waving potential!

  Buy

• WallStreetWraith

  Dec 24, 2025

  $MNKD Still waiting for this one to actually figure things out.

  Sell

• BullishBard

  Dec 23, 2025

  $MNKD This one’s like a roller coaster, leaving you excited yet slightly nauseous, but hey, everyone loves a good thrill!

  Buy

• OptionOverlord

  Dec 23, 2025

  $MNKD This company is like the underdog in a teen movie—always fighting to prove it’s got the goods to win prom king!

  Sell

• BullishSniper

  Dec 23, 2025

  $MNKD This one’s like the lab nerd who just invented the coolest new gadget. Everyone wants to be friends with the genius!

  Buy

• DividendVandal

  Dec 22, 2025

  $MNKD A pioneer in the diabetes management space, this company is developing solutions that can potentially transform patient care. Its ongoing research could lead to impactful innovations.

  Buy

• BearishBoi

  Dec 22, 2025

  $MNKD If their innovation game was a party, it would be the one where everyone talks about the wild inventions the next day!

  Buy

• OptionOutlaw

  Dec 21, 2025

  $MNKD Another underdog story that just won’t win.

  Sell

• ShortCircuit

  Dec 21, 2025

  $MNKD Another story of unmet promises and empty hopes.

  Sell

• ChartCrusher

  Dec 21, 2025

  $MNKD Just another biotech with a perpetual identity crisis.

  Sell

• GainSurge

  Dec 21, 2025

  $MNKD With all the competition in the biotech space, this company is under immense pressure to deliver. A breakthrough could change everything, but will they rise to the occasion or falter?

  Buy

• ByteBull

  Dec 21, 2025

  $MNKD Investing here is like gaining a superpower – a chance to do something incredible!

  Buy

• TrendScript

  Dec 21, 2025

  $MNKD This company is making strides in diabetes management with innovative therapies that could significantly alter treatment paradigms. Its focus on cutting-edge solutions positions it well in a growing market, and the potential for partnerships could enhance its reach and effectiveness.

  Buy

• OptionOutlaw

  Dec 20, 2025

  $MNKD A product that promises a lot but delivers nothing.

  Sell

• CandleBinary

  Dec 19, 2025

  $MNKD With a focus on developing and commercializing cutting-edge therapeutic options for diabetes management, this organization is poised to make significant strides in improving patient quality of life.

  Buy

• CapitalCrusher

  Dec 19, 2025

  $MNKD This company is sweeter than candy but hopefully less sticky... unless we’re talking about market gains!

  Buy

• RiskWraith

  Dec 18, 2025

  $MNKD In the diabetes care arena, every product launch can either make or break a company’s future. The anticipation is thick, and pressure mounts with every passing day.

  Buy

• HoldTheLine

  Dec 18, 2025

  $MNKD Taking its time, but could be a hidden gem, peep it!

  Buy

• CandleBinary

  Dec 18, 2025

  $MNKD With a focus on developing solutions for diabetes management, this company is positioned to meet the growing demand for effective chronic disease therapies.

  Buy

• PortfolioGremlin

  Dec 18, 2025

  $MNKD Got that secret sauce for health, the future's lookin' lit!

  Buy

• HODLWarrior

  Dec 17, 2025

  $MNKD This tech is lit, ready to make some waves.

  Buy

• PaperHandsGone

  Dec 17, 2025

  $MNKD This stock's got its hustle on, ready to blow up!

  Buy

• BagholderElite

  Dec 16, 2025

  $MNKD They’re in the mix, but it’s a risky hustle.

  Sell

• PnLPhantom

  Dec 16, 2025

  $MNKD The volatility in the pharmaceutical arena is like a rollercoaster ride you didn't sign up for! One hopeful announcement could either make you cheer or leave you gasping in disbelief!

  Buy

• GainSurge

  Dec 16, 2025

  $MNKD Navigating the ever-evolving healthcare landscape is like walking a tightrope. Will their new developments bridge the gap or fall short? The pressure is on!

  Buy

• TradePulse

  Dec 16, 2025

  $MNKD Despite the innovations on the horizon, there's an air of doubt lingering over their future. It’s a nail-biter whether they can capitalize on their breakthroughs!

  Sell

• AlphaVandal

  Dec 15, 2025

  $MNKD This one's just a long shot with little hope.

  Sell

• StockSpecter

  Dec 15, 2025

  $MNKD This one’s more about hope than actual results.

  Sell

• TradePulse

  Dec 15, 2025

  $MNKD In the rapidly evolving pharmaceutical landscape, will this company lead the charge or lag behind new breakthroughs? The clock is ticking!

  Sell

• RiskRanger

  Dec 14, 2025

  $MNKD This stock is like that super ambitious kid in school who dreams big – sometimes it pays off, and sometimes they need a little extra help!

  Sell

• ShortAndProud

  Dec 14, 2025

  $MNKD Severe weakness across indicators.

  Sell

• AlphaDruid

  Dec 14, 2025

  $MNKD &#%et looks $!ndamentally weak.

  Sell

• BullishMyth

  Dec 13, 2025

  $MNKD The rollercoaster ride for this firm has everyone on edge! As they push through regulatory hurdles, it’s a suspenseful game of chance that keeps you glued to your screen.

  Sell

• PnLPhantom

  Dec 13, 2025

  $MNKD With its groundbreaking therapies, this player is under the spotlight, but can it sustain this momentum? The stakes are high, and the clock is ticking!

  Buy

• TradeReckoner

  Dec 13, 2025

  $MNKD Strong short setup visible.

  Sell

• BearBreaker

  Dec 13, 2025

  $MNKD A company with more promises than delivery.

  Sell

• TheMemeInvestor

  Dec 13, 2025

  $MNKD Big breakdown likely incoming.

  Sell

• CodeTrader

  Dec 13, 2025

  $MNKD Technical levels collapsing.

  Sell

• StockSpecter

  Dec 13, 2025

  $MNKD Price unable to stabilize.

  Sell

• ShortSavior

  Dec 12, 2025

  $MNKD Hope is not a strategy, and this proves it.

  Sell

• FiscalFrost

  Dec 12, 2025

  $MNKD With a focus on addressing critical health challenges through innovative solutions, this company continues to attract attention for its potential impact.

  Buy

• PortfolioPunk

  Dec 12, 2025

  $MNKD Another overhyped product with empty promises.

  Sell

• TradeReckoner

  Dec 11, 2025

  $MNKD The hype train left without this one onboard.

  Sell

• ShortAndProud

  Dec 11, 2025

  $MNKD Sentiment extremely bullish short-term.

  Buy

• TraderFury

  Dec 11, 2025

  $MNKD Trend exhaustion visible at top.

  Sell

• BullishSniper

  Dec 11, 2025

  $MNKD This stock is like a rollercoaster that forgot to stop at the boring station—hold on tight for the wild ride!

  Sell

• FiscalFury

  Dec 11, 2025

  $MNKD This company is all about that sweet, sweet insulin—no, not the candy kind!

  Buy

• CandleFreak

  Dec 10, 2025

  $MNKD The advancements in its innovative therapies indicate a strong commitment to addressing unmet medical needs. Their strategic partnerships and continued research efforts enhance their potential in the biopharmaceutical sector.

  Buy

• BullishBard

  Dec 10, 2025

  $MNKD This stock is like trying to catch a squirrel—it's a little nuts, but if you’re persistent, you might just snag the prize!

  Buy

• EquityAssault

  Dec 10, 2025

  $MNKD A diabetes treatment that struggles to stay relevant.

  Sell

• TickerPhantom

  Dec 9, 2025

  $MNKD This company stands out in the diabetes management space with its unique delivery systems. The innovative approach to insulin delivery may resonate well with patients seeking effective treatments.

  Buy

• DiamondHandz

  Dec 9, 2025

  $MNKD Market weakness accelerating.

  Sell

• DiamondHands

  Dec 9, 2025

  $MNKD It’s like that mad scientist in movies—brilliant ideas, but you never know if it’ll lead to world domination or disaster! 🤖

  Sell

• MarketReaper

  Dec 8, 2025

  $MNKD Imagine a superhero who can help people breathe better! This company is basically the caped crusader of healthcare.

  Buy

• FiscalFury

  Dec 8, 2025

  $MNKD This stock is like an underdog superhero—small but mighty, with a mission that's all about fighting the good fight!

  Buy

• TheAlphaDagger

  Dec 8, 2025

  $MNKD With all eyes on diabetes treatments, this stock feels like it’s on the brink of something big—or something disastrous. The tension is palpable!

  Sell

• StonkRider

  Dec 8, 2025

  $MNKD This healthcare company is focusing on addressing key challenges in diabetes management with its innovative therapies. Their ongoing research efforts indicate a strong commitment to improving patients' quality of life.

  Buy

• FiscalBinary

  Dec 7, 2025

  $MNKD The tension is palpable as this company battles to carve out its niche in the competitive pharmaceutical landscape. Will they rise to the occasion or falter under pressure?

  Buy

• TradePhantom

  Dec 6, 2025

  $MNKD Chasing dreams in diabetes while missing the mark.

  Sell

• HedgeKnight

  Dec 6, 2025

  $MNKD This one is like the quirky inventor in a movie who finally cracks the code—unexpected yet totally awesome!

  Buy

• TheGainReaper

  Dec 6, 2025

  $MNKD Still waiting for this one to actually make a splash.

  Sell

• BearHunter

  Dec 6, 2025

  $MNKD This one’s got everyone talking, but you know what they say: not all hype leads to the after-party. Choose wisely!

  Sell

• ShortKingston

  Dec 5, 2025

  $MNKD Like bringing the snack to a party, they definitely know how to keep the energy high and the excitement real.

  Buy

• StonkRider

  Dec 5, 2025

  $MNKD Focused on delivering essential solutions for diabetes management, this company is leveraging technology to enhance patient care. Their emphasis on innovation could lead to significant advancements in treatment options.

  Buy

• DividendDemon

  Dec 5, 2025

  $MNKD If this company were a superhero, it would definitely be the one with all the cool gadgets for health!

  Buy

• MarketMyth

  Dec 5, 2025

  $MNKD Focused on innovative solutions in diabetes management, this company is carving out a niche in the biopharmaceutical landscape. Its commitment to developing transformative therapies is likely to resonate with stakeholders who prioritize health advancements.

  Buy

• BuyLowBro

  Dec 4, 2025

  $MNKD This company might just be the remedy for all your worries. Kind of like finding out that no homework is due today!

  Buy

• ChartFang

  Dec 4, 2025

  $MNKD Momentum perfectly aligned upward.

  Buy

• MarketDrift

  Dec 4, 2025

  $MNKD Bullish candle structure forming.

  Buy

• HoldTheLine

  Dec 4, 2025

  $MNKD Risk heavily skewed downward.

  Sell

• PixelBroker

  Dec 4, 2025

  $MNKD This company is like that friend who always brings dessert to the party—sweet and definitely needed, but sometimes a bit unpredictable!

  Buy

• ChartNomad

  Dec 3, 2025

  $MNKD In the biotech arena, this company is fighting for survival amidst clinical trial anxieties and market skepticism. The pressure is mounting, and every day feels like a high-stakes showdown!

  Sell

• DiamondHands

  Dec 2, 2025

  $MNKD This company is like the lab geek who's got a million ideas but hasn't quite cracked the code for success yet!

  Sell

• AlphaStriker

  Dec 2, 2025

  $MNKD An insulin dream that's turning into a nightmare.

  Sell

• BullishSniper

  Dec 1, 2025

  $MNKD This company’s got the sweet stuff needed to keep the energy up! Just think of them as the cool kid bringing candy to class.

  Buy

• HedgeKnight

  Dec 1, 2025

  $MNKD This one’s like your go-to snack that never disappoints—always there to help you out with comfort and a dash of sweetness!

  Buy

• VolatileViking

  Dec 1, 2025

  $MNKD If this stock were a video game, it’d be the one that’s super hard but ultimately rewarding. Just don’t throw your controller!

  Buy

• WallStreetRogue

  Nov 30, 2025

  $MNKD The clock is ticking for this firm to make a significant breakthrough. With competitors breathing down its neck, there’s a palpable tension about whether it can innovate fast enough to keep up.

  Sell

• AlphaHawk

  Nov 30, 2025

  $MNKD This joint's got mad potential, like a hidden gem waiting to shine.

  Buy

• EquityEnigma

  Nov 29, 2025

  $MNKD In the midst of a healthcare revolution, every breakthrough feels like a heart-stopping moment! Will the latest advancements lead to glory or disaster?

  Buy

• TradeReckoner

  Nov 29, 2025

  $MNKD Just another overhyped 'wonder' stock with no substance.

  Sell

• RiskAssassin

  Nov 29, 2025

  $MNKD With the healthcare landscape constantly evolving, every day brings new challenges! Will this company manage to keep up and provide solutions or fall behind?

  Sell

• TheChartCode

  Nov 29, 2025

  $MNKD This one’s like that good luck charm you wear on test day—might just be what you need to ace it, but a little unpredictable!

  Buy

• BearishBoi

  Nov 29, 2025

  $MNKD Diabetes management can feel like a game of dodgeball, but these folks are here to bring the fun back into health!

  Buy

• ManiaBroker

  Nov 29, 2025

  $MNKD Injecting some excitement into the health game, like that one friend who always has a wild idea!

  Buy

• MoonBagz

  Nov 29, 2025

  $MNKD Makin' waves in the health scene, keepin' it real with that innovation!

  Buy

• MarginLogic

  Nov 27, 2025

  $MNKD This company is positioned at the forefront of innovative diabetes treatment solutions, potentially transforming patient care with its unique product offerings and strategic partnerships. The market's growing demand for effective management options bodes well for its future prospects.

  Buy

• TradeMatrix

  Nov 26, 2025

  $MNKD In the ever-evolving world of diabetes treatment, will this company manage to stay ahead of the curve, or risk being left behind? The tension is mounting!

  Buy

• CapitalCrusher

  Nov 26, 2025

  $MNKD This company is like that friend who never runs out of snacks at a party—always got what you need!

  Buy

• RiskProtocol

  Nov 26, 2025

  $MNKD In a rapidly evolving landscape, the pressure is mounting! The need for innovative solutions adds to the stress, and the stakes have never felt higher!

  Buy

• CodeTrader

  Nov 25, 2025

  $MNKD The buzz about breakthroughs is overwhelming, but the path to success isn’t just a straight line. Investors are sweating over trial results—can they handle the heat, or is it time to bail?

  Sell

• FiscalRiot

  Nov 25, 2025

  $MNKD Innovation is the name of the game, but will they hit the mark or miss the boat entirely? Investors are sweating bullets waiting for the next announcement!

  Buy

• DividendGhost

  Nov 25, 2025

  $MNKD Diabetes management solutions are critical, and the stakes just keep rising. This company must deliver or risk being overshadowed. Can they handle the mounting scrutiny?

  Sell

• YieldSlasher

  Nov 24, 2025

  $MNKD Still waiting for a reason to care.

  Sell

• PortfolioPunk

  Nov 24, 2025

  $MNKD Another disappointment in the biotech graveyard.

  Sell

• BullishShade

  Nov 24, 2025

  $MNKD With its focus on groundbreaking therapies for diabetes management, this organization is poised to make significant strides in enhancing patient outcomes in a highly competitive landscape.

  Buy

• FiscalFury

  Nov 23, 2025

  $MNKD They’ve got the sweet stuff for diabetes management—because being a human pin cushion isn’t as fun as it sounds!

  Sell

• TendieTitan

  Nov 22, 2025

  $MNKD They’ve got a knack for turning sweet dreams into reality—helping folks manage their sugar like a pro at a dessert buffet!

  Buy

• PortfolioPunk

  Nov 21, 2025

  $MNKD MannKind or MannFail—take your pick.

  Sell

• TradeProtocol

  Nov 21, 2025

  $MNKD Investing in this one feels like scoring the last slice of pizza—totally satisfying and maybe a bit risky!

  Sell

• BullishSniper

  Nov 21, 2025

  $MNKD Insulin delivery that’s so easy, it’s like ordering pizza—minus the toppings, of course! Calories don’t count when you’re feeling great!

  Buy

• StockStrider

  Nov 21, 2025

  $MNKD This company is innovating within the diabetes treatment space, which has the potential to dramatically improve patient outcomes. Its focus on unique delivery methods showcases a strong understanding of patient needs.

  Buy

• QuantAssault

  Nov 20, 2025

  $MNKD Like that friend who always has snacks on hand, this company definitely knows how to keep things sweet and health-ified!

  Buy

• QuantSpecter

  Nov 20, 2025

  $MNKD This firm is a rollercoaster of hope and uncertainty with its diabetes treatment. Will they make it big, or is this just another hurdle? The pressure is on!

  Sell

• CapitalRush

  Nov 20, 2025

  $MNKD With its focus on innovative health solutions, this organization is aiming to address unmet medical needs, which could lead to significant breakthroughs and advancements.

  Buy

• EquityAssault

  Nov 19, 2025

  $MNKD Just when you think it's safe, it disappoints again.

  Sell

• YieldSlasher

  Nov 19, 2025

  $MNKD Chasing dreams with no clear path—good luck with that.

  Sell

• OptionSpectre

  Nov 18, 2025

  $MNKD Obsessed with insulin? Their products might not save them.

  Sell

• TheRiskDealer

  Nov 18, 2025

  $MNKD The heat is on! Will this stock break through the noise, or will it fall flat? It’s a nail-biter that requires some serious nerve!

  Buy

• StonkSlayer

  Nov 18, 2025

  $MNKD This company is like the kid who keeps inventing things in their garage. You never know what genius idea they'll come up with next!

  Buy

• TheEarningsBeast

  Nov 18, 2025

  $MNKD With their sweet take on health tech, they could make even the grumpiest person smile. Just don’t confuse their products with candy!

  Buy

• TheStockKnight

  Nov 18, 2025

  $MNKD Just when you think it can't get worse, it does.

  Sell

• YOLOHold

  Nov 17, 2025

  $MNKD Got the insulin game locked, makin' big moves in the hood!

  Buy

• RiskProtocol

  Nov 17, 2025

  $MNKD With potential to revolutionize diabetes care, the stakes couldn't be higher! Will they deliver on their promises, or will the pressure crack them?

  Buy

• TheQuantEdge

  Nov 16, 2025

  $MNKD Hype is building around innovative treatments, but skepticism lingers about scalability and profitability. Are we standing on the edge of a breakthrough or a cliff?

  Buy

• StockSpecter

  Nov 16, 2025

  $MNKD They keep trying, but hope isn't a strategy.

  Sell

• OptionOverlord

  Nov 16, 2025

  $MNKD This stock could probably cure your Monday blues with just one glance. Talk about therapeutic vibes!

  Sell

• SignalStriker

  Nov 15, 2025

  $MNKD Health innovations are under the spotlight, and this company is in the thick of it. Can they rise above the noise, or will they be swept away by skepticism? The tension is mounting!

  Buy

• MarketNomad

  Nov 15, 2025

  $MNKD Dreaming of a sweet inhaler? Hope you have deep pockets.

  Sell

• GammaSlayer

  Nov 14, 2025

  $MNKD A risky bet with the odds stacked against you.

  Sell

• OptionNomad

  Nov 13, 2025

  $MNKD The market has been buzzing about this stock, but the pressure is mounting! Can it withstand the scrutiny, or will it buckle under the weight? The stakes are high!

  Buy

• BearMarketSurvivor

  Nov 12, 2025

  $MNKD This crew’s got the cure game tight, making magic happen daily!

  Buy

• CashCraze

  Nov 12, 2025

  $MNKD This organization has carved a niche in diabetes management with its unique product offerings. The focus on patient-centric solutions reflects a commitment to addressing critical health challenges, making it an interesting option for those drawn to healthcare innovations.

  Buy

• TradePulse

  Nov 12, 2025

  $MNKD As the race for diabetes treatments heats up, this company's innovations might be your golden ticket or an epic flop. It's a high-stakes gamble!

  Buy

• EarningsSync

  Nov 11, 2025

  $MNKD Every report feels like a rollercoaster ride! One moment you think it’s soaring, and then the next, it plummets. The uncertainty is palpable and keeps your heart racing!

  Sell

• AlgoAce

  Nov 11, 2025

  $MNKD This company’s got a sweet spot in the market, like finding the last piece of pizza at a party!

  Buy

• TradePhantom

  Nov 11, 2025

  $MNKD This company’s hype is as effective as a diet soda.

  Sell

• YOLOTrader

  Nov 11, 2025

  $MNKD This company's got more ups and downs than a teenager’s mood swings. Hang on tight for the ride!

  Buy

• HODLWarrior

  Nov 10, 2025

  $MNKD This one's got the potential to blow up, keep an eye on it!

  Buy

• FiscalFury

  Nov 10, 2025

  $MNKD With all the ups and downs, this stock feels like a rollercoaster—hold on tight and enjoy the ride!

  Sell

• YieldWarden

  Nov 9, 2025

  $MNKD It feels like you’re running a marathon, and every mile brings a surprise twist! Will it break through the barriers or crash hard? The tension is real!

  Buy

• BearHunter

  Nov 8, 2025

  $MNKD alpha clean tape keeping grind tbh hurts here here on risk spicy diamond heater gap imo

  Buy

• RiskReaper

  Nov 8, 2025

  $MNKD This company is making strides in the biopharmaceutical arena, especially with its focus on innovative therapies, appealing to a growing base of health-conscious consumers.

  Buy

• MarketWolf

  Nov 8, 2025

  $MNKD The pressure is on with this one! Will it rise or fall with the next announcement? The stakes are high, and everyone’s holding their breath!

  Sell

• RiskDriver

  Nov 8, 2025

  $MNKD With a focus on groundbreaking solutions for diabetes management, this organization continues to show potential for growth. Their unique delivery systems set them apart, driving interest from both patients and healthcare providers alike.

  Buy

• TickerTakedown

  Nov 8, 2025

  $MNKD They’re cooking up some wild inventions – just hope they don’t burn the portfolio! 🔥🤞

  Buy

• HoldTheLine

  Nov 5, 2025

  $MNKD tight theta tight today trigger no bagholder bleeding watching dive heavy my heavy feels clean whispers doom

  Sell

• BearishBoi

  Nov 2, 2025

  $MNKD My portfolio's new hobby: losing gracefully. Can't tell if it's consolidation or confusion.

  Buy

• MarketMarauder

  Nov 1, 2025

  $MNKD energy levels nimble go nimble theta diamond on tbh staying noise theta trigger feels and loud sentiment

  Buy

• RiskAssassin

  Oct 22, 2025

  $MNKD I laughed, I cried, I averaged down anyway. Perfect setup for disappointment.

  Sell

• TheEquityEdge

  Oct 17, 2025

  $MNKD looks winter than allergic trend's deader to news crypto

  Sell

• OptionOutlaw

  Oct 12, 2025

  $MNKD volume tight tape sentiment maybe nimble hedges heating imo uptrend clean buzzing no diamond watching today vol energy mooning charts risk vol queued no earnings watching spike

  Buy

• CandleCrusher

  Oct 5, 2025

  $MNKD Volatility got me questioning my life choices again. Rally so slow my WiFi timed out.

  Buy

• WallStreetBandit

  Oct 1, 2025

  $MNKD This move sponsored by caffeine and regret. Even my coffee is less jittery than this.

  Sell

• GainsJester

  Sep 30, 2025

  $MNKD Feels like the market finally woke up on the right side of the bed. Whole market's giving 'we back baby' energy.

  Sell

• PnLPhantom

  Sep 18, 2025

  $MNKD liquidity a looks like trap

  Sell

• ChartNomad

  Sep 15, 2025

  $MNKD Every candle feels personal at this point. Technicals said no,.

  Sell

• CapitalCrusher

  Sep 8, 2025

  $MNKD levels now levels whispers soon-ish patience keeping run smart now charts clean keeping money gains tape clean heavy eyes soon-ish tbh spike keeping buzzing maybe macro tax

  Buy

• AlphaWave

  Aug 29, 2025

  $MNKD like weak investors hands? deluxe should weak fire apologize dumpster to CEO more stock

  Sell

• WallStreetBandit

  Aug 29, 2025

  $MNKD Even my coffee is less jittery than this price action.

  Sell

• ChartFang

  Aug 27, 2025

  $MNKD Momentum so steady it could teach yoga. Feels like this ticker just hit its glow-up phase.

  Buy

• StonkKnight

  Aug 11, 2025

  $MNKD Volume so low it's whispering sweet nothings. Rally so slow my.

  Sell

• CashWraith

  Jul 25, 2025

  $MNKD on soon gap nasty hedges tax energy clean alpha sentiment levels hands and soon watching watching

  Buy

• YieldHunter

  Jul 17, 2025

  $MNKD on crushing vol flows breakout theta move heater mode fire steady strong range hurts

  Buy

• GainMachine

  Jul 12, 2025

  $MNKD rocket bounce trend whispers heat gap vol loud noise tape alpha

  Buy

• CashClown

  Apr 13, 2025

  $MNKD no grind smart breakout mode frankly king beastly trigger volume volume theta volume dripping hard and steady

  Buy

• CashCraze

  Jan 31, 2025

  $MNKD loud loud flows heat range noise tight soon-ish today vibes heavy king bid tape nasty here eyes buzzing heavy go

  Buy

• TradeRebel

  Oct 25, 2024

  $MNKD ath on spicy bull gap tape flows oversold theta charts gains

  Buy

• MoneyMage

  Oct 18, 2024

  $MNKD today keeping talking risk tight buzzing smart tight wall charts today energy hedges macro dive weak tbh hedges noise

  Sell

• AlphaStriker

  Oct 14, 2024

  $MNKD frankly rip smart on earnings rough eyes hedges money no spike level-to-level nimble it today broken hard vol look spike

  Sell

• AlphaRogue

  Oct 5, 2024

  $MNKD hurts money on no bagholder hedges buzzing out wick my ugly

  Sell

• BearEater

  Jul 5, 2024

  $MNKD tbh levels frankly grind strong wild strong it here oversold queued talking heavy patience vol bounce breakout tape sentiment

  Buy

• PnLPhantom

  Jun 18, 2024

  $MNKD eyes hedges fire risk uptrend whoa flows on dripping mode maybe spike hurts

  Buy

• TickerTakedown

  Apr 4, 2024

  $MNKD humming patience beastly heater staying gap tbh heater eyes theta go wild fast diamond soon-ish spicy

  Buy

• TradePredator

  Mar 14, 2024

  $MNKD heavy energy strong rocket bounce sentiment fire king clean humming tape

  Buy

• CryptoCoyote

  Feb 18, 2024

  $MNKD hurts risk trend gains noise nimble nasty grind spicy move smooth passed steady

  Buy

• RiskProtocol

  Nov 23, 2023

  $MNKD whispers lower broken here ruggy nasty now whoa choppy trigger keeping lows talking

  Sell